Selective, Nontoxic CB<sub>2</sub> Cannabinoid <i>o</i>‑Quinone with in Vivo Activity against Triple-Negative Breast Cancer Paula Morales Sandra Blasco-Benito Clara Andradas María Gómez-Cañas Juana María Flores Pilar Goya Javier Fernández-Ruiz Cristina Sánchez Nadine Jagerovic 10.1021/acs.jmedchem.5b00078.s001 https://acs.figshare.com/articles/journal_contribution/Selective_Nontoxic_CB_sub_2_sub_Cannabinoid_i_o_i_Quinone_with_in_Vivo_Activity_against_Triple_Negative_Breast_Cancer/2186719 Triple-negative breast cancer (TNBC) represents a subtype of breast cancer characterized by high aggressiveness. There is no current targeted therapy for these patients whose prognosis, as a group, is very poor. Here, we report the synthesis and evaluation of a potent antitumor agent in vivo for this type of breast cancer designed as a combination of quinone/cannabinoid pharmacophores. This new compound (<b>10</b>) has been selected from a series of chromenopyrazolediones with full selectivity for the nonpsychotropic CB<sub>2</sub> cannabinoid receptor and with efficacy in inducing death of human TNBC cell lines. The dual concept quinone/cannabinoid was supported by the fact that compound <b>10</b> exerts antitumor effect by inducing cell apoptosis through activation of CB<sub>2</sub> receptors and through oxidative stress. Notably, it did not show either cytotoxicity on noncancerous human mammary epithelial cells nor toxic effects in vivo, suggesting that it may be a new therapeutic tool for the management of TNBC. 2015-03-12 00:00:00 CB 2 receptors compound nonpsychotropic CB 2 cannabinoid receptor breast cancer TNBC cell lines antitumor Nontoxic CB 2 Cannabinoid quinone vivo